The New England Journal of Medicine has published the detailed results of the IB1001-301 Phase 3, Pivotal study with N-acetyl-L-leucine (IB1001) for the treatment of NPC
Read the full announcement from IntraBio here:
Statement NEJM 4B1
.docx
Download DOCX • 15KB
Bremova-Ertl et al. 2024 NEJM
.pdf
Download PDF • 694KB
The New England Journal of Medicine (NEJM) has published the detailed results of the IB1001-301 Phase 3, Pivotal study with N-acetyl-L-leucine (IB1001) for the treatment of Niemann-Pick disease Type C (NPC): https://www.nejm.org/doi/full/10.1056/NEJMoa2310151 (note - the article/ quick take video, are available to download / view for free if you register an account).
To join our fight, as well as fund vital research for a cure, support the Australian NPC Disease Foundation in its goals of "Research. Cure. Persevere."
Ways to support NP-C in Australia:
Check out upcoming events
Shop at our online NPC store
Fundraise your way! Check our free resources and inspo online.